Provided by Tiger Trade Technology Pte. Ltd.

Voyager Therapeutics

3.71
+0.03000.82%
Post-market: 3.710.00000.00%16:49 EST
Volume:282.27K
Turnover:1.04M
Market Cap:206.28M
PE:-1.71
High:3.75
Open:3.66
Low:3.58
Close:3.68
52wk High:5.66
52wk Low:2.65
Shares:55.60M
Float Shares:45.82M
Volume Ratio:0.42
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1691
EPS(LYR):-1.1272
ROE:-46.09%
ROA:-24.53%
PB:0.94
PE(LYR):-3.29

Loading ...

Voyager Therapeutics to Present at Multiple Major Investor Conferences

Reuters
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)

TIPRANKS
·
Feb 05

Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel

Reuters
·
Jan 09

Voyager Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 13, 2025

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)

TIPRANKS
·
Nov 12, 2025

Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

TIPRANKS
·
Nov 12, 2025

Voyager Therapeutics Inc : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
Nov 12, 2025

Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo

TIPRANKS
·
Nov 12, 2025

Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)

TIPRANKS
·
Nov 11, 2025

Wedbush Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics files $400M mixed securities shelf

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics Inc Files for Mixed Shelf Offering of up to $400 Mln- SEC Filing

THOMSON REUTERS
·
Nov 11, 2025

Voyager Therapeutics price target lowered to $11 from $12 at Leerink

TIPRANKS
·
Nov 11, 2025

Voyager Therapeutics, Transition Bio entered into drug discovery collab

TIPRANKS
·
Nov 10, 2025

Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens

Reuters
·
Nov 10, 2025

Voyager Therapeutics and Transition Bio Partner to Develop Small Molecule Therapies for ALS and FTD

Reuters
·
Nov 10, 2025

Voyager Therapeutics reports third quarter revenue of $13.4 million

Reuters
·
Nov 10, 2025

BRIEF-Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million

Reuters
·
Nov 10, 2025

Voyager Therapeutics Q3 Operating Income USD -30.594 Million

THOMSON REUTERS
·
Nov 10, 2025

Voyager Therapeutics Inc - Transition Bio Eligible for up to $500M in Milestones

THOMSON REUTERS
·
Nov 10, 2025